Navigation Links
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Date:4/8/2008

riod B) phases of the study, the adverse reactions in pediatric patients were similar in type and frequency to those seen in adult patients. This was also seen in patients who participated in the open-label (Period C) extension period.

The overall frequency of adverse events in Period A was 70 percent; infections occurred at a frequency of 36 percent. The most common infections were upper respiratory tract infection and nasopharyngitis. The infections resolved without sequelae, and the types of infections were consistent with those commonly seen in outpatient pediatric populations. Other events that occurred at a prevalence of at least five percent were headache, nausea, diarrhea, cough, pyrexia and abdominal pain. A total of six serious adverse events [acute lymphocytic leukemia, ovarian cyst, varicella infection, disease flare (2) and joint wear] were reported during the initial four months of treatment with ORENCIA. There was one case of a hypersensitivity reaction (0.5 percent). During Periods A, B and C, acute infusion-related events occurred at a frequency of four percent, two percent and three percent, respectively, and were consistent with the types of events reported in adults. Upon continued treatment in the open-label extension period, the types of adverse events were similar except for a single patient diagnosed with multiple sclerosis while on open-label treatment.

About Juvenile Idiopathic Arthritis (JIA)

JIA -- also commonly known as Juvenile Rheumatoid Arthritis (JRA) -- is the most common chronic rheumatic disease in children, and it is an important cause of short-term and long-term disability(3). It is an autoimmune disease that causes chronic pain, stiffness and swelling of the joints(4), which may ultimately lead to joint damage and deformities(5). The disease usually begins before the age of 16(6). Juvenile arthritis may affect up to one in every 1,000 children in the United States(6). ORENCIA(R) (abatacept) is one treatment
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... http://www.researchandmarkets.com/research/7jx6nq/china ) has announced the addition of ...  report to their offering.       ... cardiovascular disease in China ... and changes in consumption concept, dietary habit, ...
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... 17, 2014  Ameritox SM , the nation,s leader ... Thomas Smith , M.D., as Chief Medical Officer. ... offering scientific resources for healthcare providers, patients and managed ... positions at a variety of healthcare companies that have ... pain and behavioral health sides of Ameritox,s business. He ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Ameritox Appoints New Chief Medical Officer 2
... Associates, of New Jersey awarded General Program Prize Paper at ... ... 18 Researchers at,Reproductive Medicine Associates of New Jersey (RMA) ... Reproductive Medicine (ASRM),for developing a novel technology making it possible ...
... Corporation,announced today that enrollment has completed in a ... to enhance memory. The,IMPACT ("Improvement in Memory with ... than five hundred adults aged 65+,seeking to improve ... Principal Investigators for the IMPACT trial are Elizabeth ...
Cached Medicine Technology:Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 2Researchers Develop New Procedure to Screen All 46 Human Chromosomes to Identify Abnormalities in Embryos 3Study Demonstrates Mindful Approach to Aging 2Study Demonstrates Mindful Approach to Aging 3
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
(Date:10/20/2014)... National Teen Driver Safety Week is October 19-25, ... Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining the National ... drivers to talk to their teens and always set the ... are the leading cause of death for U.S. teens. In ... and 859 (42%) of those teen drivers were killed in ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... Criminal Fine is Largest Individual Corporate Criminal Fine in ... American pharmaceutical giant Eli Lilly and Company today agreed ... its drug Zyprexa for uses not approved by the ... announced today. This resolution includes a criminal ...
... Jan. 15 For the first time in Ohio,s,history, ... in a,statewide effort to make Ohio the safest place ... The Cardinal Health Foundation, the Ohio Business ... and the Ohio Children,s,Hospital Association today announced the formation ...
... to Private FirmsPHILADELPHIA, Jan. 15 /PRNewswire/ -- ... Communications for Centocor, Inc., an operating company of ... of a public relations consultancy, Pitch360 Incorporated ( ... communications, and issues management consultancy that leverages its ...
... BOSTON ─ (January 15, 2009) Tufts University has ... Health (NIH) to design an obesity prevention program ... D. Economos, PhD, the clinical trial will randomize ... age children living in Somerville, Mass., and follow ...
... nonpartisan Employee Benefit Research Institute (EBRI) today published a ... involved in capping the tax exclusion for employment-based health ... year,s expected debate over overhauling the nation,s health care ... been a policy goal of both parties as far ...
... Health Group announced today that in the year ... hospitals with local employers reached more than 70,000 ... rising healthcare costs as America confronts such growing ... At the same time, hospitals partnering with Aegis ...
Cached Medicine News:Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Ohio Business, Health Care Leaders Join Together to Improve Patient Safety, Reduce Costs in Ohio Hospitals 2Health News:Ohio Business, Health Care Leaders Join Together to Improve Patient Safety, Reduce Costs in Ohio Hospitals 3Health News:Former Johnson & Johnson Executive Gives Big Voice to Small Companies 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 2Health News:Tufts receives NIH grant to study obesity prevention in new immigrants 3Health News:New Research From EBRI: Study Examines Issues in Capping Tax Exclusion of Health Coverage 2Health News:Hospital-Employer Partnerships Growing as Employers Seek Ways to Improve Health and Manage Dollars in Tough Economic Times 2
Dual-bay Dyad thermal cycler chassis, does not include the Alpha units (requires 2)...
... 24-well x 0.2ml sub-ambient block and automatic ... Heating rates: up to 3C/second; Accurate block ... uniformity: better than 0.5C within 15 seconds; ... directory program storage of up to 60 ...
... The Gene Cycler unit is an inexpensive personal ... for the PCR process. Lightweight, with a small ... almost anywhere, including the researcher's desk. , The ... researchers who do not have access to a ...
... a high quality, compact thermal cycler. In addition ... Mastercycler personal offers first-rate operational flexibility. Its universal ... x 0.2 ml tubes, 16 x 0.5 ml ... grid format. Like the Mastercycler and the Mastercycler ...
Medicine Products: